Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Bill aims to protect patient access to affordable generic drugs.
The problem
Generic drug prices may be rising or access may be limited due to market practices, potentially affecting patients who rely on affordable medications.
The proposal
The bill establishes protections and possibly new regulations to ensure consumers can access generic drugs at reasonable prices and prevent anticompetitive practices.
The impact
Patients needing affordable medications, pharmaceutical companies, and healthcare systems would be affected by changes to generic drug pricing and availability policies.
Protecting generic drug access could help patients afford necessary medications. Many people rely on generic drugs because they cost much less than brand-name versions. Keeping these affordable helps people stay healthy.
More generic drug availability encourages competition among manufacturers. When companies compete, they lower prices and improve quality. This benefits the entire healthcare system and consumers.
Generic drugs save money for insurance companies and government programs. Lower drug costs mean less spending on healthcare overall. This frees up money for other medical services.
Ensuring generic access gives patients more treatment options. Patients can choose affordable alternatives without sacrificing quality. This supports patient autonomy in healthcare decisions.
New regulations may increase costs for pharmaceutical manufacturers. Smaller generic drug companies might struggle to meet requirements. This could reduce the number of companies producing generics.
Restrictions on pricing and market practices might reduce profits for drug manufacturers. Lower profits could decrease investment in developing new medications. This might slow medical advances.
The bill's enforcement and oversight could require significant government spending. Implementing new regulations takes time and resources. The true cost to taxpayers is uncertain.
Heavy regulations might cause some manufacturers to exit the market. Reduced manufacturers could create generic drug shortages. This could ironically harm the goal of access.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.